---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019094"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:32:01.432332+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q1 2022 net loss of $7.0M; secures $100.5M private placement

## Summary
- Net loss for Q1 2022 was $7.0M, compared to $7.8M in Q1 2021.
- Cash and cash equivalents at March 31, 2022 were $33.8M; subsequently received $100.5M gross proceeds from April private placement.
- Research and development expenses increased to $8.5M from $4.8M, driven by clinical trial costs.
- ENLIGHTEN Phase 3 program for LYR-210 enrollment ongoing; ENLIGHTEN II initiation targeted mid-2022.
- BEACON Phase 2 trial for LYR-220 first patient treated in Australia; Part 2 expected in U.S. in Q2 2022.

## SEC filing metadata
- accession: 0001564590-22-019094
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000156459022019094/0001564590-22-019094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000156459022019094/lyra-8k_20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019094
- JSON: https://secwatch.observer/filing/0001564590-22-019094.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.